Imugene LtdASX: IMU

Two Additional Complete Responses in azer-cel Ph1b trial

· Issued by Imugene Ltd

Filed with ASX · · 6 pages · English

Summary by 6ix AI

The trial is now open for enrollment in CAR T naïve indications for other lymphomas, and an additional update is expected in the coming months. Imugene plans to meet with the US FDA regarding a pivotal study for azer-cel based on these positive results.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Imugene Ltd on 6ix

In the deck

Story so far

Earlier from Imugene

Later from Imugene

All Imugene news releases